Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.TCRT · Entity 8339 | EVP, Operations | March 30, 2022 | April 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date March 30, 2022 · Filed April 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2032-03-29 | Direct | 350,000 |
Reported balance
After 2022-03-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-30 · Grant · Acquired 350,000 · Balance 350,000 F1: One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three months after January 1, 2022, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three months after January 1, 2022, subject to the Reporting Person's continued service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2022 Filed Apr 1, 2022 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0000899243-22-013117 · doc4.xml · derivative · entry 1 De Groot Eleanor · CIK 0001780420 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-03-29 F1 · derivative.exercise_date: One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three months after January 1, 2022, subject to the Reporting Person's continued service through each such date. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 17:20 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 20,132 | $1.27 | $25,567.64 |
DisclosureSEC source: 0000899243-21-049739 · doc4.xml · nonDerivative · entry 1 De Groot Eleanor · CIK 0001780420 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,106 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:26 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 381,188 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-018628 · doc4.xml · derivative · entry 2 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,188 Underlying: Common Stock · 381,188 shares Expires 2031-03-04 F2 · derivative.exercise_date: 1/16th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:26 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 50,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018628 · doc4.xml · nonDerivative · entry 1 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,238 F1 · shares: 12,707 shares shall vest on 12/31/2021 and 12,706 shares shall vest on each of 12/31/2022, 12/31/2023 and 12/31/2024. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:03 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 21,620 | $2.72 | $58,806.40 |
DisclosureSEC source: 0001209191-21-002174 · doc4.xml · nonDerivative · entry 1 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,413 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:47 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 82,600 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005781 · doc4.xml · derivative · entry 2 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,600 Underlying: Common Stock · 82,600 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:47 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 53,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005781 · doc4.xml · nonDerivative · entry 1 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,033 F1 · shares: 17,900 shares shall vest on each of 12/31/2020, 12/31/2021 and 12/31/2022. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:06 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 24,890 | $4.55 | $113,249.50 |
DisclosureSEC source: 0001209191-20-001170 · doc4.xml · nonDerivative · entry 1 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,333 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.